Jul 31, 2026 06:46AM
Jul 23, 2026 08:00AM
Jul 23, 2026 08:00AM
May 12, 2026 04:01PM
Apr 7, 2026 12:33PM
Apr 7, 2026 08:15AM
Apr 7, 2026 08:00AM Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Apr 7, 2026 08:00AM
Mar 26, 2026 04:01PM
Jan 21, 2026 06:10AM
Dec 29, 2025 11:25AM
Dec 26, 2025 06:41AM
Dec 11, 2025 08:04AM
Nov 20, 2025 04:01PM Inhibikase advances IKT-001 to phase 3 study for pulmonary arterial hypertension
Nov 20, 2025 04:01PM
Mar 31, 2025 06:45AM
Nov 14, 2024 08:37AM
Oct 21, 2024 09:05AM
Aug 14, 2024 04:25PM
Jun 17, 2024 08:05AM
Jun 5, 2024 08:05AM Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
May 20, 2024 08:01AM
May 20, 2024 08:01AM
May 15, 2024 08:00PM
May 15, 2024 08:45AM
May 15, 2024 08:45AM
May 9, 2024 08:00AM
Apr 18, 2024 04:30PM Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
Apr 18, 2024 04:30PM
Apr 3, 2024 08:05AM
Apr 3, 2024 08:05AM
Mar 27, 2024 04:15PM
Feb 28, 2024 04:06PM
Feb 28, 2024 04:05PM
Feb 7, 2024 07:55AM Inhibikase Therapeutics (IKT) Reports Prelim Outcomes of Pre-NDA Meeting with the FDA on IkT-001Pro
Feb 7, 2024 07:55AM
Dec 19, 2023 08:31AM
Dec 19, 2023 08:30AM
Dec 4, 2023 08:35AM
Dec 4, 2023 08:35AM
Nov 14, 2023 04:30PM
Oct 16, 2023 07:07AM Inhibikase Therapeutics (IKT) Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
Oct 16, 2023 07:00AM
Oct 4, 2023 08:31AM
Oct 4, 2023 08:30AM
Aug 17, 2023 08:32AM
Aug 17, 2023 08:30AM
Aug 14, 2023 04:20PM
Jun 22, 2023 08:06AM Inhibikase Therapeutics (IKT) Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Jun 22, 2023 08:05AM

327,799 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All